Eagle Pharmaceuticals, Inc. (EGRX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol EGRX
- Company Eagle Pharmaceuticals, Inc.
- Price $1.99
- Changes Percentage 13.71
- Change 0.24
- Day Low $1.7
- Day High $1.99
- Year High $6.37
- Year Low $0
- Market Cap $25,786,818
- Price Avg 50 EMA (D) $1.45
- Price Avg 200 EMA (D) $1.89
- Exchange OTC
- Volume 302
- Average Volume 8,085
- Open $1.7
- Previous Close $1.75
- EPS 0.85
- PE 2.34
- Earnings Announcement 2024-11-18 13:30:00
- Shares Outstanding $12,958,200
Company brief: EAGLE PHARMACEUTICALS, INC. (EGRX )
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Mr. Michael Graves
- https://www.eagleus.com
- US
- N/A
- 02-12-2014
- US2697961082
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.